|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
Inovio Pharmaceuticals acquired by a private equity firm
|
|
gptkbp:ceo
|
gptkb:Joseph_Kim
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:HPV_vaccine
gptkb:Canada
gptkb:United_States
gptkb:vaccine
ongoing
completed
Phase 2
terminated
|
|
gptkbp:collaborations
|
gptkb:Duke_University
gptkb:University_of_Pennsylvania
gptkb:University_of_California,_San_Diego
|
|
gptkbp:focus
|
DNA-based immunotherapies
|
|
gptkbp:focus_area
|
oncology
infectious diseases
|
|
gptkbp:founded
|
gptkb:2000
|
|
gptkbp:founder
|
gptkb:Joseph_Kim
|
|
gptkbp:funding
|
grants
public offerings
private placements
|
|
gptkbp:headquarters
|
gptkb:San_Diego,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Inovio Pharmaceuticals
|
|
gptkbp:invention
|
DNA vaccine technology
|
|
gptkbp:investment
|
gptkb:Vanguard_Group
gptkb:Black_Rock
gptkb:State_Street_Corporation
gptkb:investors
|
|
gptkbp:market_cap
|
approximately $500 million
|
|
gptkbp:number_of_employees
|
approximately 100
|
|
gptkbp:partnership
|
gptkb:Merck_&_Co.
gptkb:The_Bill_&_Melinda_Gates_Foundation
|
|
gptkbp:product
|
VGX-3100
INO-4800
INO-1400
INO-1401
INO-1800
INO-4801
INO-4802
INO-4803
INO-4804
INO-4805
INO-4806
INO-5401
|
|
gptkbp:stock_symbol
|
INO
|
|
gptkbp:technology
|
Electroporation
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.inovio.com
|
|
gptkbp:bfsParent
|
gptkb:SK_Bioscience
|
|
gptkbp:bfsLayer
|
7
|